Moderna Chases Gulf Partnerships and a 2028 Breakeven as Madrid Readout Looms
Published on 09/27/2026 at 13:32 | Editorial boerse-global.de
Moderna's ambitions no longer fit inside a single vaccine franchise. The Cambridge-based biotech is stitching together a global web of research, manufacturing and government alliances — and courting the deep-pocketed Gulf states in the process.
Chairman Noubar Afeyan sat down Friday with Saeed bin Mubarak Al Hajeri, a minister of state of the United Arab Emirates. Talks centered on concrete investment and cooperation opportunities in advanced pharmaceutical manufacturing, spanning joint research and development as well as local production capacity. It is a familiar playbook: Middle Eastern governments are pouring capital into homegrown life-science sectors to prepare for a post-fossil-fuel era, and Moderna stands to diversify its production and development footprint well beyond its Western strongholds.
Three Pillars, One Platform
The push abroad runs parallel to an effort to reshape how capital markets see the company. CEO Stéphane Bancel and development chief David Berman took the stage Wednesday at the Bernstein Insights Healthcare Leaders and Disruptors Forum, sketching a broad mRNA platform rather than a one-product story. Three pillars are meant to carry future growth: conventional vaccines, oncology and rare diseases.
That repositioning is not just rhetoric. Moderna now counts five approved products, and its cancer candidate Intismeran has already been given to roughly 3,000 patients across more than 40 countries in clinical studies. Management is sticking to a goal of reaching breakeven in 2028, a target reiterated at the Morgan Stanley Global Healthcare Conference in mid-September, according to media reports.
Should investors sell immediately? Or is it worth buying Moderna?
The platform's reach keeps widening. Reuters reported that the World Health Organization said on September 16 that a Moderna Ebola vaccine candidate will be evaluated in a clinical trial targeting the Bundibugyo outbreak in the Democratic Republic of Congo.
A Stock That Has Already Priced In a Lot
Investors have rewarded the story with striking force. The shares closed Friday at EUR 174.30, having touched a 52-week high of EUR 177.12 earlier in the session. Since the start of the year the stock is up 556 percent — a run that leaves little room for disappointment.
The next strategic milestone is already circled on calendars. Three abstracts on Intismeran autogene have been accepted for the European Society for Medical Oncology congress, running October 23–27 in Madrid. The highlight falls on October 24, when Phase 3 data in resected stage IIB to IV melanoma will be presented during the prestigious Presidential Symposium. Moderna will host an investor webcast the same day at 19:00 CET.
The Gap Between Platform Hype and Valuation Models
Whether a pipeline can justify the hefty valuation before reliable cash flows arrive from the new therapeutic areas is the question skeptics keep raising. The distance between optimistic platform hopes and the sober models of traditional analysts is widening again.
What Moderna is attempting is to anchor a disruptive key technology permanently in the world's healthcare infrastructure. The talks in the Emirates show that ambition does not stop at national borders. For shareholders, the lens is shifting: the share price will depend less on short-term vaccine orders than on whether the leap from specialized developer to globally integrated technology group succeeds. The groundwork is being laid right now.
Ad
Moderna Stock: New Analysis - 27 September
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
